Effects of genistein, estrogen and progesterone therapies on bladder morphology and M2, M3 receptor expressions in oophorectomized rats

Basit Öğe Kaydı
dc.contributor.authorTurgut A.
dc.contributor.authorGoruk N.Y.
dc.contributor.authorSak M.E.
dc.contributor.authorDeveci E.
dc.contributor.authorAkdemir F.
dc.contributor.authorKeles A.N.
dc.contributor.authorNergiz Y.
dc.date.accessioned2024-04-24T18:46:11Z
dc.date.available2024-04-24T18:46:11Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractAims: Investigating the effects of estrogen, estrogen/progesterone combination and genistein therapy on the expression of M2 and M3 receptors located on bladder walls and comparing the morphological and degenerative changes exerted on bladder walls. Materials and methods: A total of 50 adult Sprague-Dawley female rats were randomly divided into five groups. Rats other than the sham group were ovariectomized. OVX group (control group) received water, OVX+G group received 10 mg/kg genistein, OVX+E group received 0.014 mg/kg 17-ß estradiol, OVX+E+P group received 0.014 mg/kg 17-ß estradiol plus 0.028 mg/kg drospirenone per day. Results: When compared with the sham group, in the OVX group higher collagen fibre (CF): smooth muscle (SM) ratio, relatively increased fibrosis, oedema, space between detrusor smooth muscle fascicles, cytoplasmic vacuoles, and total M2, and M3 expression were observed. Relative to the OVX group, decreased CF: SM ratio and fibrosis in the OVX+G, OVX+E, and OVX+E+P groups, decreased oedema, spaces between detrusor muscle fascicles and cytoplasmic vacuoles in the OVX+G group and lesser total M2, and M3 expression in the OVX+G, OVX+E and OVX+E+P groups were observed. Conclusion: Genistein therapy regresses unfavourable morphological changes effecting postmenopausal bladder and increases in M2 and M3 receptor expression more effectively than estrogen and estrogen/progesterone combination. Besides, genistein therapy almost completely regresses degenerative changes; however, estrogen and estrogen/progesterone combination therapies do not improve these degenerative changes except for fibrosis. We think that genistein will favourably contribute both to the conduction of more comprehensive studies in the future concerning its use in postmenopausal urinary incontinence where estrogen and estrogen/progesterone combination therapies do not provide any improvement and etiopathogenesis of urinary incontinence.en_US
dc.identifier.endpage916en_US
dc.identifier.issn0393-6384
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-84903446754
dc.identifier.scopusqualityN/A
dc.identifier.startpage907en_US
dc.identifier.urihttps://hdl.handle.net/11468/25100
dc.identifier.volume30en_US
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherActa Medica Mediterraneaen_US
dc.relation.ispartofActa Medica Mediterranea
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEstrogenen_US
dc.subjectGenisteinen_US
dc.subjectMenopauseen_US
dc.subjectMuscarinic Receptoren_US
dc.subjectOophorectomized Raten_US
dc.subjectUrinary İncontinenceen_US
dc.titleEffects of genistein, estrogen and progesterone therapies on bladder morphology and M2, M3 receptor expressions in oophorectomized ratsen_US
dc.titleEffects of genistein, estrogen and progesterone therapies on bladder morphology and M2, M3 receptor expressions in oophorectomized rats
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu